NCT03019029

Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.

Detailed description

Patients with pathologically proven amyloidosis involving the peripheral nervous system will undergo 18-F Florbetapir PET/MR on a GE (General Electric Healthcare) SIGNA PET/MR scanner. A control arm comprised of patients with pathologically-confirmed non-amyloid causes of peripheral neuropathy will also undergo 18-F Florbetapir PET/MR scanning. all images will be reviewed for peripheral nerve uptake.

Conditions

• Amyloidosis

Interventions

Type	Name	Description
OTHER	18-F Florbetapir PET/MR scan	18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner

Timeline

• Start date: 2017-03-13
• Primary completion: 2022-03-24
• Completion: 2022-03-24
• First posted: 2017-01-12
• Last updated: 2026-03-16

Locations

1 site across 1 country: United States